Abstract
BackgroundConventional dendritic cells (DCs) are essential mediators of anti-tumor immunity and the efficacy of anti-PD-1 checkpoint immunotherapies.1 Recent studies suggest that tumor-mediated development of a sub-population of tolerogenic DCs plays...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have